CD4 and tuberculosis: If the recent evidence suggesting a FujiLAM sensitivity in the range of 53 to 75% in HIV-negative patients from endemic TB regions can be confirmed, then a recommendation independent of CD4 count and potentially independent of HIV status might be possible [14, 15].